[1] |
YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan.
Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
|
[2] |
HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong.
Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
|
[3] |
CAO Fang, QIN Kairong, ZHENG Guoshuang, ZHAO Dewei.
Exploring the intervention mechanism of Ginkgo biloba for steroid-induced necrosis of the femoral head based on network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 266-275.
|
[4] |
MA Guangli, ZHANG Jing.
Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
|
[5] |
HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang.
Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
|
[6] |
PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua.
Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 178-183.
|
[7] |
LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang.
Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
|
[8] |
CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke.
Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
|
[9] |
GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun.
General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
|
[10] |
YANG Sheng, WANG Deguo.
Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
|
[11] |
LIU Yanzhi, WANG Yan, LIU Kaili, ZHOU Wenhua, ZHU Ping, WANG Yingli, DU Shouying.
Inhibition and mechanism of Xihuang pill on mice bearing hepatoma H22 tumor
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 754-761.
|
[12] |
YAO Qian, CHEN Yun, SHANG Juan, XI Xiaoyun, CHEN Ying, GU Xiao, JU Wenzheng, ZOU Jiandong, LU Su, XU Meijuan.
Investigation of potential pharmacodynamic substances and mechanism of Qingxin-zishen prescription decoction in treatment of menopause syndrome based on HPLC-Q-TOF-MS/MS and network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 481-497.
|
[13] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Evinacumab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
|
[14] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Inclisiran
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
|
[15] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
|